Icentia’s CardioSTAT Received the US FDA’s 510(k) Clearance for the Diagnosis of Patients with Cardiac Disorders
Shots:
- The US FDA has approved Icentia’s ambulatory, continuous ECG monitoring solution, CardioSTAT, that relies on a wire free, single-use recorder. The CardioSTAT solution provides physicians the choice of multiple monitoring durations ranging from 24hrs. to 14days
- The solution features a pay-by-duration model to enable cost savings while addressing clinical needs whereas its streamlined workflow allows healthcare institutions to perform data analysis themselves with cost-effective proprietary software from Icentia
- The company had previously launched CardioSTAT across Canada and the UK & CardioSTAT has been prescribed to over 170,000 patients
Ref: PR Newswire | Image: Icentia
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
